Abstract: An active phospholipid of the formula ##STR1## wherein R.sub.1 is aliphatic of 14 to 24 carbon atoms saturated or containing 1 or 2 unsaturations, R.sub.3 is a residue selected from the group consisting of choline, ethanolamine, glycerol, serine, inositol, ethanol, n-propanol, n-butanol and ethylene glycol and ##STR2## is an active group in the 2-position of the glycerol released by phospholipases and cosmetic and dermatological compositions containing the same useful for treating or caring for the skin.
Abstract: A compound selected from the group consisting of a syn isomer of a compound of the formula ##STR1## in the R or S form or in the form of an R, S mixture wherein R us selected from the group consisting of ##STR2## R and R' are individually selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, halogen, CO.sub.2 --Q, ##STR3## CH.sub.2 --SQ, Q and Q' are individually hydrogen or alkyl of 1 to 4 carbon atoms, P, P' and P" are individually alkyl of 1 to 4 carbon atoms optionally substituted by one of the substituents R and R' the dotted line indicating that P and P' can optionally form with the nitrogen atom to which they are linked a heterocycle with 5 or 6 links, R.sub.b and R.sub.c are individually selected from the group consisting of an equivalent of an alkali metal, an alkaline earth metal, magnesium, ammonium and an amine organic base or A and A' are the remainder of an easily cleavable ester group or CO.sub.2 A is CO.sub.
Abstract: A cDNA coating for a protein having saccharose phosphate synthetase activity and a vector permitting the expression of a protein having saccharose phosphate synthetase activity under the control of a promoter directing the said expression.
Type:
Grant
Filed:
April 26, 1995
Date of Patent:
June 29, 1999
Assignee:
Roussel Uclaf
Inventors:
Charles Van Assche, Danielle Lando, Jean Michel Bruneau, Toni Alois Voelker, Monica Gervais
Abstract: A compound of the formula ##STR1## wherein R is .dbd.O or ##STR2## and the rings A and B are selected from the group consisting of ##STR3## K is oxo or a protector group of oxo of the formula ##STR4## n is 2 or 3 and R.sub.1 is an ether or ester remainder, K' is oxo or a protector oxime, hydrazone or semicarbazone group and the wavy lines symbolize an isomer mixture, a process for their preparation and their use as intermediates.
Type:
Grant
Filed:
October 8, 1997
Date of Patent:
April 6, 1999
Assignee:
Roussel Uclaf
Inventors:
Jean Buendia, Remi Chauvin, Michel Vivat
Abstract: A biologically active, non-glycosylated recombinant human Interleukin 2 (R-hIL.sub.2) in reduced form, process for its preparation and method of use.
Type:
Grant
Filed:
October 17, 1995
Date of Patent:
February 23, 1999
Assignee:
Roussel Uclaf
Inventors:
Danielle Lando, Philippe Riberon, Pierre Yves Abecassis
Abstract: An expression cassette, operable in a recombinant host, comprising a heterologous DNA coding sequence encoding a protein, which is functional, alone or in cooperation with one or more additional proteins, of catalyzing an oxidation step in the biological pathway for conversion of cholesterol into hydrocortisone, which step is selected from the group consisting of:the conversion of cholesterol to pregnenolone;the conversion of pregnenolone to progesterone;the conversion of progesterone to 17.alpha.-hydroxy-progesterone;the conversion of 17.alpha.-hydroxyprogesterone to cortexolone;the conversion of cortexolone to hydrocortisone, and thecorresponding control sequences effective in said host.
Type:
Grant
Filed:
April 6, 1995
Date of Patent:
February 9, 1999
Assignee:
Roussel Uclaf
Inventors:
Herman Slijkhuis, Eric Bastiaan Smaal, Gerardus Cornelis Maria Selten
Abstract: The invention relates to the products of formula (I): ##STR1## in which: R.sub.1 =represents hydrogen, aryl, arylcarbonyl, arylthio, alkylcarbonyl,R.sub.2, R.sub.3 represent in particular halogen, mercapto, acyl, carboxy, nitro, cyano, amino, carbamoyl, R.sub.4, --OR.sub.4 with R.sub.4 representing in particular hydrogen, alkyl, alkenyl, alkynyl, acyl, amino, --(CH.sub.2).sub.m1 --S(O).sub.m2 --X--R.sub.10 with m1=0 to 4, m2=0 to 2, X represents a single bond or --NH--, --NH--CO--, --NH--CO--NH--,and R.sub.10 represents alkyl, alkenyl or aryl, and Y represents optionally substituted aryl, these products being in all isomer forms and salts, their use as medicaments.
Abstract: Crystallized anhydrous zilpaterol hydrochloride having less than 5% of the crystals with a size of less than 15 microns and at least 95% of the crystals having a size of less than 250 microns and a process for its preparation and novel intermediates.
Abstract: A compound of the formula ##STR1## having progestomimetic activity, wherein the substituents are as defined in the specification and compositions of a compound of formula I and an estrogen compound.
Type:
Grant
Filed:
May 22, 1997
Date of Patent:
November 10, 1998
Assignee:
Roussel Uclaf
Inventors:
Jacques Biton, Jean-Pierre Marchandeau, Robert Azerad, Isabelle Lacroix
Abstract: An isolated antibody that specifically binds a peptide coded by a nucleotide sequence coding for a variable region of .beta.-chain of an human T lymphocyte receptor, said nucleotide sequence having a nucleotide sequence selected from any of:the nucleotide sequences of SEQ ID Nos. 2 to 19.
Abstract: Novel compounds of the formula ##STR1## wherein the substituents are defined as in the application and their salts with non-toxic, pharmaceutically acceptable acids and bases having 5-.alpha.-reductase inhibiting activity and a process and intermediates for their preparation.
Abstract: The present invention relates to new nucleotide sequences coding for variable regions of the .alpha. chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses.
Abstract: Compounds of the formula ##STR1## in all possible racemic, enantiomeric and diastereoisomeric forms and their non-toxic, pharmaceutically acceptable salts with acids and bases having antagonistic properties for angiotensin II receptors and a process and novel intermediates for their properties.
Type:
Grant
Filed:
January 5, 1996
Date of Patent:
October 6, 1998
Assignee:
Roussel Uclaf
Inventors:
Francois Clemence, Michel Fortin, Jean-Luc Haesslein
Abstract: A biologically active, non-glycosylated recombinant human Interleukin 2 (R-hIL.sub.2) in reduced form, process for its preparation and method of use.
Type:
Grant
Filed:
February 12, 1996
Date of Patent:
September 29, 1998
Assignee:
Roussel Uclaf
Inventors:
Danielle Lando, Philippe Riberon, Pierre Yves Abecassis
Abstract: Products of formula (1), wherein R.sub.1 is particularly ##STR1## alkyl, alkylthio or alkoxy; R.sub.2 is particularly halogen, --S--R, --O--R or --C(OH)(R)--COOH, where R is alkyl or alkenyl; R.sub.3 is particularly carboxy, acyl, halogen, alkyl, alkenyl or alkylthio; and R.sub.4 is particularly --(CH.sub.2).sub.m1 --COOR.sub.4, --(CH.sub.2).sub.m1 --CONHR.sub.14, --(CH.sub.2).sub.m1 --CN, --SO.sub.2 --NH--SO.sub.2 --R.sub.14, 13 NH--SO.sub.2 --R.sub.14, --PO.sub.3 R.sub.14, or --NH--SO.sub.2 --CF.sub.3, where m1 is 0-4 and R.sub.14 is hydrogen, alkyl or alkenyl; are useful for preparing pharmaceutical compositions for treating disorders resulting from abnormal stimulation of angiotensin II receptors AT.sub.1 and AT.sub.2.
Type:
Grant
Filed:
August 30, 1996
Date of Patent:
September 22, 1998
Assignee:
Roussel Uclaf
Inventors:
Alain Corbier, Pierre DePrez, Michel Fortin, Jacques Guillaume
Abstract: Sucrose phosphate synthase (SPS), its process for preparation, its cDNA, and utilization of cDNA to modify the expression of SPS in the plant cells are provided.
Type:
Grant
Filed:
September 9, 1999
Date of Patent:
February 24, 2004
Assignees:
Calgene, LLC., Roussel Uclaf
Inventors:
Charles Van Assche, Danielle Lando, Jean Michel Bruneau, Toni Alois Voelker, Monica Gervais
Abstract: A compound of the formula ##STR1## wherein R.sub.1 is --CN, --NO.sub.2 or halogen, R.sub.2 is --CF.sub.3 or halogen, --A--B-- is of ##STR2## X is --O-- or --S--, R.sub.3 is hydrogen, alkyl, alkenyl or alkynyl of up to 12 carbon atoms, aryl and aralkyl of up to 12 carbon atoms, all optionally substituted by --OH, halogen, --SH, --CN, acyl and acyloxy of up to 7 carbon atoms, --aryl, --O--aryl, --O--aralkyl --S-- aryl of up to 12 carbon atoms the aryl and aralkyl being optionally substituted by halogen, --CF.sub.3, alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl or alkynyloxy with the sulfur being optionally oxidized to sulfone or sulfoxide, free, esterified, amidified or salified carboxy, --NH.sub.
Type:
Grant
Filed:
February 27, 1997
Date of Patent:
November 10, 1998
Assignee:
Roussel Uclaf
Inventors:
Martine Gaillard-Kelly, Francois Goubet, Daniel Phiibert, Jean-Georges Teutsch